Genelux Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $114.0M
- Price
- $2.52
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.79%
- Volume
- 550.9K
About
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Quick stats
Shares outstanding45.2M
Computed float38.3M
Float / shares84.6%
Cash runway (months)7.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001231457
Websitehttps://www.genelux.com
AI Summary
AI-generated1/6
minorbullishclinical trial
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Genelux published a peer-reviewed case report in Frontiers in Oncology showing a platinum-relapsed small cell lung cancer patient achieved 16.7 months progression-free survival after a single intravenous course of Olvi-Vec followed by platinum/etoposide rechallenge, exceeding the 14.3-month PFS from her first-line platinum therapy.
The patient's target lesions shrank 84.6%, and tumor reduction at four cycles of rechallenge was deeper than during first-line treatment (-78.9% vs -67.8%), supporting the hypothesis that Olvi-Vec remodels the tumor microenvironment and re-sensitizes tumors to platinum chemotherapy.
The case comes from the Phase 1b dose-escalation portion of the OLVI-VEC-202-SCLC trial (NCT07136285), co-sponsored with and conducted in China by licensing partner Newsoara HYK Biopharmaceuticals; enrollment is ongoing, with dose-finding updates from this trial and the Phase 2 VIRO-25 NSCLC trial expected in 2026.
Management cautions the single-patient result does not establish safety or efficacy; Genelux's pivotal asset test remains the Phase 3 OnPrime/GOG-3076 ovarian cancer trial underway in the U.S.
Red flags
- Single-patient case report — company explicitly states it does not establish safety or efficacy or predict similar outcomes
- SCLC data generated in a China-based trial conducted by licensing partner Newsoara rather than directly by Genelux
- Clinical-stage, pre-revenue company; next meaningful catalysts (dose-finding updates) not expected until 2026